Cointime

Elevian

company

About

Elevian develops medicines that restore youthful regenerative capacity with the potential to treat and prevent many age-related diseases.

  • 11 - 50

Highlights

Total Funding Amount
$55M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Series A
Last Funding Money Raised
$40M
Industries
Biopharma,Biotechnology,Therapeutics
Founded date
Jul 15, 2017
Number Of Employee
11 - 50
Operating Status
Active

Elevian’s founders discovered circulating blood factors that regulate aging, including GDF11, which broadly stimulate regeneration of brain, heart, pancreas, muscle, and other tissues. Elevian is developing therapeutics that stimulate regenerative capacity, to treat and prevent age-related disease.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$55M
Elevian has raised a total of $55M in funding over 2 rounds. Their latest funding was raised on Sep 16, 2021 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 16, 2021 Series A $40M 1 — — Detail
Nov 24, 2020 Seed $15M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
Elevian is funded by 2 investors. Kuelbs Family Office and SAVEarth Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Kuelbs Family Office — Series A
SAVEarth Fund — Seed
Cointime
เนื้อหา
บริษัท